Founded in 2021 and located in Suzhou Anhui Province, with a total investment of 1 billion yuan and an area of 300 acres, it is one of the production bases of APIs and intermediates of Farmasino Co., Ltd., and one of the largest production bases of fosfomycin products in China. The first phase of the project has been completed, which can achieve an annual output of 1000 tons of fosfomycin series APIs and 1000kg of sucrose octasulfate, etc., and the second phase of the project is under construction.

Located in Nanjing Economic Development Zone, Jiangsu Province, covering an area of 20,000 square meters, it has built a chemical drug research and development center and a preparation production workshop (dosage forms include oral solid preparations, oral solutions, inhalation preparations, injections, external drugs, anti-tumor preparations, etc.). It is expected to produce 1.5 billion tablets of solid preparations, 1 billion capsules, 30 million bags of powders, 60 million bottles of multi-dose oral liquid, and 1.2 billion bottles of single-dose oral liquid per year.

The production workshops comply with Chinese GMP standards,and approved many other countries’GMP inspection,like Uganda,Tanzania,Kenya,Uzbekistan,Yemen,Peru,Columbia etc.We also have obtained 400+ quality regulation registration certificates.
Small Volume Injection Site:7 production lines,annual production volume 2 billion ampoules.

Large Volume Injection Site:3 production lines,annual production volume 30 million bottles.

Oral Dosages Site:3 production lines,annual production volume 10 billion tablets and 2 million capsules.

Powder for Injection Site:4 production lines,1.5 billion vials.

Located in "China Medical City" in Taizhou, Jiangsu, is one of FarmaSino's formulation production bases. Its main business includes export-oriented MAH and other entrusted productions. The production workshops comply with GMP standards and specialize in manufacturing tablets and hard capsule formulations. Zonta Pharma has obtained production approvals for 2 products, Cefalexin Capsules and Chloramphenicol Capsules. It holds a Drug Manufacturing License for capsule formulations, tablet formulations, oral liquid formulations, and granule formulations. With a total of 6 pharmaceutical production lines, including an annual capacity of 1 billion tablets/capsules and 30 million bottles of oral liquid formulations, Zonta Pharma can efficiently fulfill large-scale drug processing and production requirements for both domestic and international clients.